Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
For patients with chronic hives that don't respond to antihistamines, omalizumab may do more than just calm the itch. A new study found that 3 months of treatment significantly reduced disease activity scores and lowered systemic inflammation markers — suggesting the drug works on deeper biological pathways. Over half of patients achieved well-controlled disease, with a third reaching complete remission.
For patients whose chronic hives won't quit despite antihistamines, omalizumab is proving to be a powerful ally — and not just for symptom relief. A new observational study published in the Irish Journal of Medical Science found that 3 months of omalizumab treatment in 30 patients with antihistamine-resistant chronic spontaneous urticaria (CSU) led to dramatic improvements in disease activity and measurable reductions in systemic inflammation.
Patients received 300 mg of subcutaneous omalizumab every 28 days. Beyond easing symptoms, the drug also reduced leukocyte and neutrophil counts, the neutrophil-to-lymphocyte ratio, CRP levels, erythrocyte sedimentation rate, and D-dimer levels — pointing to broad anti-inflammatory and anticoagulant effects.
By the Numbers:
Why it matters: These findings suggest omalizumab's benefits in CSU extend well beyond itch relief, influencing the body's inflammatory and clotting systems. However, the small sample size and lack of a control group mean larger studies are needed before baseline lab tests can be used to predict who will respond best.
